Piper sees GLP-1 drugs having limited impact on diabetes device market


Diabetes Background Conceptual Design.

Tashatuvango/iStock via Getty Images

Piper Sandler said it sees GLP-1 drugs as having only a limited impact on the market for devices to treat type 2 diabetes and virtually no impact on those to treat type 1, at least for the next several years.

Source link

Leave A Reply

Your email address will not be published.